All Eyes on Congress as US User Fee Programme Expiry Date Nears
This article was originally published in SRA
Executive Summary
All eyes will be on the US Congress when it returns from its summer recess at the beginning of September. The legislature left for the holidays without reauthorising a vitally important piece of pharmaceutical legislation - the prescription drug user fee act - and now time is running out.